NEW YORK — Arcis Biotechnology has signed an agreement to license its nucleic acid sample preparation and preservation technology to Spanish microRNA diagnostics developer Mirnax Biosens, the companies said today.
Under the terms of the deal, Mirnax will use Arcis' technology to improve the stability of miRNA biomarkers for early disease detection. The firms will also work together to develop a microfluidic device that integrates their respective technologies.
Additional terms were not disclosed.
"This latest agreement demonstrates the wide breadth of applications for our nucleic acid sample preparation technology including clinical diagnostics, which is an area that we look forward to exploring further," Arcis CSO Jan Rogers said in a statement.
Earlier this month, UK-based Arcis inked a distribution agreement for its sample prep products with Opentrons, and in May it formed a comarketing partnership with Andrew Alliance. In late 2018, Arcis licensed its technology to Teleflex for use in the development of a diagnostic assay.